

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

JACOBS ET AL.

Serial No.: to be assigned

Group: 1633

Filed: December 8, 2003

Examiner: S. Kaushal

For: USE OF BACTERIUM FOR MANUFACTURE OF A VACCINE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

December 8, 2003

Dear Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. These references were cited in the parent application USSN 09/492,206, and thus no copies are enclosed.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the

information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,

  
\_\_\_\_\_  
Mark W. Milstead  
Attorney for Applicants  
Registration No. 45,825

Akzo Nobel N.V. Patent Department  
Intervet Inc.  
P.O. Box 318  
405 State Street  
Millsboro, DE 19966  
Tel: (302) 934-4395  
Fax: (302) 934-4305

INFORMATION DISCLOSURE CITATION  PTO-1449	Attorney Docket No.	Serial No.
	I 99452 US C1	To be assigned
	Applicant Jacobs et al	
	Filing Date	Group
	December 8, 2003	To be assigned

### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA	6,120,775	9/19/2000	Jacobs et al			
	AB	6,344,201	2/2002	Maurelli et al			
	AC	5,895,654	4/1999	Hartford et al			
	AD	4,521,513	6/1985	Russel			
	AE	5,961,985	10/1999	Sprouse et al			
	AF	5,895,756	4/1999	Barrett et al			
	AG						
	AH						
	AI						

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Translation
	AJ	0 786 518 A	7/30/97	EP	
	AK	0 894 500 A	2/3/99	EP	
	AL	2 033 233 A	5/21/80	GB	
	AM				
	AN				
	AO				
	AP				
	AQ				

### OTHER DOCUMENTS

	AR	LOHMAN B L ET AL: "Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques.", JOURNAL OF MEDICAL PRIMATOLOGY (FEB-MAY) 23 (2-3) 95-101
	AS	TITBALL ET AL: "Vaccination against bubonic and pneumonic plague", 2001, Vaccine 19: 4175-4184
	AT	HARALAMBIEV: "The immunological response of calves after submucosal application of a live vaccine against parainfluenza-3- and adenovirus", 1974, 397-400
	AU	CURTISS III, ET AL: "Strategies for the Use of Live Recombinant Avirulent Bacterial Vaccines for Mucosal Immunization", 1996, ACADEMIC Press, pp. 499-511
	AV	CURTISS, R: "Bacterial Infectious Disease Control by vaccine development", J. Clin. Invest. 110(8): 1061-1066, 2002
	AW	FORREST: "Indirect Measurement of intestinal immune response to an orally administered attenuated bacterial vaccine." Infect. Immun. 60(5): 2023-2029, 1992
	AX	
Examiner		Date Considered

Express Mail EV 389656045 US